Skip to main content
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Subscribe
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Articles
FDA Approvals
Magrolimab, First CD47 Antibody, Shows Promise in Combination with Azacitidine in Unfit Patients with Acute Myeloid Leukemia
Wayne Kuznar
Read More
FDA Approvals
Oral Vodobatinib Elicits Durable Responses in Heavily Pretreated Patients with Chronic Myeloid Leukemia
Chase Doyle
Read More
Pevonedistat plus Azacitidine Combination Improves Outcomes versus Azacitidine Monotherapy in High- Risk Myelodysplastic Syndromes
Wayne Kuznar
Read More
Practice Management
Financial Toxicity Intervention in Patients with Hematologic Malignancies Effective, Improves Adherence and Quality of Life
Chase Doyle
Read More
FDA Approvals
,
Multiple Myeloma
,
Oncology
Xpovio Approved for Patients with Relapsed or Refractory Multiple Myeloma
Read More
FDA Approvals
,
Lung Cancer
,
Oncology
Tagrisso Approved as Adjuvant Therapy for NSCLC with EGFR Mutations
Read More
FDA Approvals
,
Lymphoma
Xalkori Approved for Anaplastic Large-Cell Lymphoma and ALK Mutation in Young Patients
Read More
FDA Approvals
First-Line Mosunetuzumab Safe and Effective in Older Patients with Diffuse Large B-Cell Lymphoma
Chase Doyle
Read More
Practice Management
ASH 2020 Presidential Symposium Highlights Innovations Aimed to Improve Patient Access to Treatment
Wayne Kuznar
Read More
Multiple Myeloma
,
Oncology
Belantamab Induces Deep Responses in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
Read More
23
24
25
26
27
28
29
Page 26 of 244
Results 251 - 260 of 2434